clinical trial · NCT05371964
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
MyelofibrosisImetelstat sodiumRuxolitinib
brief summary
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.
started
May 4, 2022
primary completion
Feb 1, 2027
completion
Aug 1, 2028
last updated
Jan 6, 2026
official title
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol